Edition:
United Kingdom

Crane Co (CR.N)

CR.N on New York Stock Exchange

93.23USD
17 Jan 2018
Change (% chg)

$0.93 (+1.01%)
Prev Close
$92.30
Open
$92.74
Day's High
$93.40
Day's Low
$92.51
Volume
50,056
Avg. Vol
91,403
52-wk High
$93.57
52-wk Low
$67.62

Chart for

About

Crane Co. (Crane) is a manufacturer of engineered industrial products. The Company operates through four segments, including Fluid Handling, Payment & Merchandising Technologies, Aerospace & Electronics, and Engineered Materials. The Fluid Handling segment is a provider of engineered fluid handling equipment, including Process... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $4,805.59
Shares Outstanding(Mil.): 59.60
Dividend: 0.33
Yield (%): 1.64

Financials

  Industry Sector
P/E (TTM): -- 26.34 16.44
EPS (TTM): -- -- --
ROI: -- 9.64 10.61
ROE: -- 11.65 14.21

BRIEF-Crane Co Says Entered $550 Million 5-Year Revolving Credit Agreement

* CRANE CO SAYS ENTERED $550 MILLION 5-YEAR REVOLVING CREDIT AGREEMENT - SEC FILING

21 Dec 2017

BRIEF-Crane Co Says If Merger Deal Terminated Under Certain Circumstances, Crane & Co Inc To Pay Co Termination Fee Of $36 Mln

* CRANE CO SAYS IF MERGER DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CRANE & CO INC TO PAY CO TERMINATION FEE OF $36 MILLION - SEC FILING Source text: (http://bit.ly/2jU5ooc) Further company coverage:

05 Dec 2017

BRIEF-Diversified Industrial Crane Co. To Acquire Crane & Co Inc For $800 Million

* DIVERSIFIED INDUSTRIAL CRANE CO. TO ACQUIRE BOSTON-BASED CRANE & CO., INC. (“CRANE CURRENCY”) FOR $800 MILLION

05 Dec 2017

BRIEF-Edge Therapeutics appoints Rosemary Crane to Board of Directors

* Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors

19 Sep 2017

BRIEF-Crane Co Q2 earnings per share $1.14

* Q2 earnings per share view $1.17 -- Thomson Reuters I/B/E/S

24 Jul 2017

Competitors

Earnings vs. Estimates